PCV19 ONE-YEAR COSTS FORACUTE CORONARY SYNDROME IN PATIENTS WITH AND WITHOUT REVASCULARIZATION DURING THE INITIAL HOSPITALIZATION  by Sidney, S et al.
A124 Abstracts
PCV18
ECONOMIC EVALUATION OF ORAL THERAPIES FOR
PULMONARY ARTERIAL HYPERTENSION
Harnett J1,Van Engen A2, Schoeman O2
1Pﬁzer Inc, New York, NY, USA, 2Quintiles Consulting, Hoofddorp,The
Netherlands
OBJECTIVES: The objective of this study was to create an eco-
nomic model for evaluation of two oral therapies for pulmonary
arterial hypertension (PAH) in the US. METHODS: Using a
Markov model, expected outcomes and costs for PAH patients
treated with either RevatioTM (sildenaﬁl citrate) or TracleerTM
(bosentan) were evaluated over a 1 year period. The health states
in the model were based on the World Health Organization func-
tional class I to IV and death. Transition probabilities and utili-
ties were based on the results of the SUPER-1 clinical trial for
RevatioTM. Treatment effect was estimated using relative risk of
improvement in 6-minute walk tests for sildenaﬁl and bosentan
based on pivotal clinical trials. Costs were derived from average
wholesaler price and Medicare reimbursement data. Sensitivity
analyses were performed in order to test the strength of the con-
clusions of the analysis over a range of structural assumptions,
probability estimates and value judgments. RESULTS: Sildenaﬁl
therapy was associated with signiﬁcant cost savings ($3.0 million
per 100 patients per year) in comparison with bosentan. Life-
year and QALY differences between sildenaﬁl and bosentan were
found to be negligible. CONCLUSIONS: The results show that
sildenaﬁl is more cost-effective than bosentan mainly due to the
large difference in medication costs (in favor of sildenaﬁl).
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ONE-YEAR COSTS FOR ACUTE CORONARY SYNDROME IN
PATIENTS WITH AND WITHOUT REVASCULARIZATION
DURING THE INITIAL HOSPITALIZATION
Sidney S1, Sorel M1, Quesenberry Jr CP1, McCollam PL2
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OBJECTIVES: Revascularization procedures are often carried
out during hospitalizations for acute coronary syndrome (ACS).
Our objectives are to estimate the costs during the ﬁrst year of
follow-up after initial (index) hospitalization for ACS stratiﬁed
by whether or not revascularization took place at this hospital-
ization. METHODS: This consisted of Kaiser Permanente
Medical Care Program Nothern California patients age >40
years, and hospitalized with ACS during January 1, 1999 to
December 31, 2000, and without ACS hospitalization during 6
months prior. Costs expressed are those incurred by the health
plan. RESULTS: A total of 14,852 patients met inclusion crite-
ria. Mean age was 67.2 years; 63.9% were male. The distribu-
tion of revascularization during index hospitalization was 2457
CABG (16.5%), 3257 PCI (21.9%), and 9138 no procedure
(61.5%). Index total hospitalization costs were: CABG ($34,307
+ 26,515), PCI ($14,863 + $11,665), no procedure ($11,059 +
16,497). One-year follow-up costs were highest for no procedure
[$17,669 + 32,510 ($7,781 median)], intermediate for CABG
[$12,763 + 22,676 ($5,670)] lowest for PCI [$12,297 + 22,197
($4,336)]. Percent of total costs by type of resource used (clinic,
hospital, pharmacy, respectively) were for CABG 36.5%, 45.3%,
9.2%, for PCI 30.1%, 57.5%, 10.4%, and for no procedure
24.3%, 62.6%, and 7.5%. As expected, follow-up costs were
considerably impacted by whether or not revascularization was
performed. One-year revascularization rates were 15.0% for the
PCI group, 14.3% for no procedure, and only 2.2% for CABG.
One-year mean follow-up costs with and without revasculariza-
tion were: CABG ($28,867 with and $12,401 without revascu-
larization), PCI ($34,673 with and $8,344 without revascular-
ization), no procedure ($39,476 with and $14,020 without
revascularization). CONCLUSIONS: While hospitalization for
ACS with revascularization procedure was associated with
higher costs than hospitalization with no procedure, one-year
follow-up costs were higher in the no procedure group, largely
due to higher hospitalization costs.
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MARKOV-BASED ECONOMIC ANALYSIS OF NESIRITIDE IN
ACUTE DECOMPENSATED HEART FAILURE
Blackburn JC1, DiDomenico R1, Hilleman DE2, Schumock GT1,
Walton SM1
1University of Illinois at Chicago, Chicago, IL, USA, 2Creighton
University, Omaha, NE, USA
OBJECTIVES: Acute decompensated heart failure (ADHF) leads
to frequent hospital admissions and mortality; and represents a
signiﬁcant economic burden to patients, providers, and society.
Nesiritide may reduce downstream resource utilization and
improve patient outcomes when used early in the treatment.
METHODS: A Monte Carlo simulation for a hypothetical
cohort of 10,000 patients, based on a Markov model, was used
to estimate from the hospital perspective the expected values of
outcomes of interest. The model incorporates complications of
therapy (atrial ﬁbrillation and renal failure), location of inpatient
care (intensive care unit, inpatient ward, or emergency depart-
ment only), and hospital readmissions. Three stages of disease
were included within each cycle of the model: well (survive
ADHF hospitalization without suffering ADHF readmission),
sick (survive ADHF hospitalization but suffer ADHF readmis-
sion), and death. Transition probabilities were calculated from
prior published clinical trials. Hospital costs were obtained from
a pilot study conducted at Creighton University Medical Center.
The model was run over six cycles of one month each. RESULTS:
Based on the results of the Monte Carlo simulation, nesiritide
was dominant over standard therapy because it both reduces
costs and leads to a greater life expectancy. The average hospi-
tal costs per patient treated with nesiritide and standard therapy
were $9856 (SD ± $4676) and $10,953 (SD ± $5573) respec-
tively. Cost differences were mostly attributable to a lower prob-
ability of readmission for patients receiving nesiritide. The
percentage of patients who required 2 or more readmissions in
the nesiritide and in the standard therapy group were 25% and
31% respectively. Survival at six months also favored nesiritide.
CONCLUSIONS: Our model predicts that nesiritide, given
within 24 hours of hospitalization for ADHF, would lead to a
reduction in overall costs and the number of total readmissions,
and may decrease mortality over 6 months compared to stan-
dard therapy.
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COSTS OF DIAGNOSTIC PROCEDURES OF
INTERVENTIONIST CARDIOLOGY IN THE SOCIAL SECURITY
MEXICAN INSTITUTE (IMSS)
Mould J1, Salinas-Escudero G1, Martinez-Valverde S2,
Garduño-Espinosa J1, Duran-Arenas L1
1Social Security Mexican Institute, Mexico City, Mexico, 2Social
Security Research Unit, Mexico City, Mexico
OBJECTIVES: An efﬁcient assignation of resources in the service
of hemodinamy requires the knowledge of costs of possible diag-
nostic procedure’s combinations. Currently, in Mexico the costs
for these procedures are very general and incomplete. The objec-
tive of this study was to estimate the direct and indirect medical
cost of different interventionist cardiology diagnostic procedures
